AEON · AEON Biopharma, Inc.

📣 What AEON Says Is Next

• fourth quarter of 2026 · “AEON intends to incorporate the FDA’s feedback and advance the study under an investigational new drug application (“IND”), which the Company expects to submit in the fourth quarter of 2026.”
  Company press release, Sep 30, 2026 · SEC filing
• in 2026 · “The Company believes the FDA’s feedback provides a clear framework for the remaining analytical components of its biosimilar development program and plans to complete the majority of its analytical comparability program in 2026. o AEON currently plans to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program to support approval of ABP-450 as a biosimilar to BOTOX Ò across all approved therapeutic indications.”
  Company press release, Mar 30, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Jun 2024 · Phase 2 · Results Expected · Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
  Registry primary completion date, not a results date
• Jul 2023 · Phase 2 · Results Expected · Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-4
  Registry primary completion date, not a results date
• Jul 2022 · Phase 2 · Results Expected · A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervica
  Registry primary completion date, not a results date

📊 Drug Pipeline

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AEON holds $3.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.2M/quarter from operations, an estimated runway of 3.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

• Cash runway 3 months +40
• ATM program on file since Jun 2025 +15
• Shelf registration (S-3, Feb 2026) +10
• Going-concern doubt in the latest 10-Q +15As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that these condensed consolidated financial statements are issued. 10-Q, Aug 2026
• Raised after last reported balance sheet (Jul 2026) -10

Recent financing filings on SEC EDGAR:

• Jul 15, 2026 · Underwritten offering · 424B4
• Jul 8, 2026 · S-1 registration · S-1
• Feb 9, 2026 · Shelf registration · S-3
• Jan 21, 2026 · Private placement (8-K Item 3.02) · 8-K
• Dec 15, 2025 · Private placement (8-K Item 3.02) · 8-K
• Nov 13, 2025 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AEON files for a raise →

👥 Who Owns AEON

Share count 49,882,790 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.